William Looney, Editor-in-Chief, last month took home the award for "Best Commentary"
Pharm Exec's Editor-in-Chief William Looney was honored March 10 at American Business Media's Neal Awards for "Best Commentary" for his monthly editorial columns.
The Jesse H. Neal Awards were established in 1954 to recognize and reward editorial excellence in independent business publications. Reflecting the changing face of business media, the awards now encompass 19 categories of work and this year attracted more than 600 nominated entries from publications with a combined circulation of some 20 million readers. The awards were handed out at the Mandarin Oriental Hotel in New York at a luncheon sponsored by the B-to-B industry's trade group, American Business Media (ABM), and chaired by Bill McDowell, VP/Editorial Director, Marketing & Technology Group.
January 2010 http://bit.ly/FTEJan2010
Nominees were evaluated through a two-tiered screening process by an independent panel of judges drawn largely from both the professional ranks and academic schools of journalism. Three finalists were selected in each category by the ABM Editorial Committee, after which a Board of Judges comprised of 11 members made the final decisions on the winners.
March 2010 http://bit.ly/FTEMar2010
Awards were presented by Paul Maidment, Principal and Editor-in-Chief of Bystander Media, and CBS News Correspondent Rebecca Jarvis (shown at left presenting the Neal Award to Mr. Looney). Jarvis cited Mr. Looney's winning columns as topical and provocative in asserting the biopharmaceutical industry's need to repair a declining level of public trust—a breach that threatens to override the ultimate value it provides to society through contributions to medical progress. In receiving his Neal Award for Best Commentary, Mr. Looney commented: "After many years in the industry—struggling to parse both sides of an 'Alice in Wonderland' looking glass—it is great to get paid to have an opinion! I am truly honored."
July 2010 http://bit.ly/FTEJuly2010
Pharm Exec will continue to let you, our readers, know what we think, in a distinctive voice designed to keep all parties in this vital industry—including ourselves—honest to the truth.
Cell and Gene Therapy Check-in 2024
January 18th 2024Fran Gregory, VP of Emerging Therapies, Cardinal Health discusses her career, how both CAR-T therapies and personalization have been gaining momentum and what kind of progress we expect to see from them, some of the biggest hurdles facing their section of the industry, the importance of patient advocacy and so much more.